Study Claims Big Savings From Generic Drug Settlements

, The National Law Journal

   | 1 Comments

The United States' health care system saved $25.5 billion between 2005 and 2012 due to patent settlements that moved generic pharmaceuticals to market in advance of brand-name drugs' patent expiration date, according to research financed by generic drug manufacturers.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Continue to Lexis Advance®

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

  • Mike

    Another decision for big business and defeat for the consumer. The court upheld price fixing since the FTC doesn't have the $ or manpower to stop the "pay to delay" settlements. So it is the consumer who will pay for the delay.

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202610171338

Thank you!

This article's comments will be reviewed.